Headlines about GlycoMimetics (NASDAQ:GLYC) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GlycoMimetics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.6888550219032 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of GlycoMimetics (NASDAQ GLYC) traded down 3.31% on Friday, hitting $11.11. 409,065 shares of the stock traded hands. The stock has a 50 day moving average of $11.17 and a 200 day moving average of $8.48. GlycoMimetics has a one year low of $3.82 and a one year high of $16.94. The company’s market cap is $363.55 million.

GlycoMimetics (NASDAQ:GLYC) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Equities analysts anticipate that GlycoMimetics will post ($1.22) earnings per share for the current year.

GLYC has been the topic of several research reports. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Tuesday, July 18th. Stifel Nicolaus restated a “buy” rating and issued a $13.00 target price on shares of GlycoMimetics in a report on Tuesday, June 6th. Jefferies Group LLC dropped their target price on shares of GlycoMimetics from $16.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, June 6th. Cowen and Company restated a “buy” rating on shares of GlycoMimetics in a report on Tuesday, May 9th. Finally, Canaccord Genuity restated a “buy” rating and issued a $12.00 target price on shares of GlycoMimetics in a report on Friday, May 19th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. GlycoMimetics presently has a consensus rating of “Hold” and a consensus target price of $14.20.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/25/glycomimetics-glyc-earning-somewhat-positive-news-coverage-study-shows.html.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Insider Buying and Selling by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Stock Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related stocks with our FREE daily email newsletter.